Gilead exercises option on Kymera’s CDK2 degrader for $45M

Gilead Sciences, a major American biopharmaceutical company, has exercised its exclusive option to license KT-333, a novel CDK2 protein degrader drug candidate, from Kymera Therapeutics, a biotechnology firm based in Watertown, Massachusetts. The strategic move, announced on March 18, 2025, secures Gilead's rights to the asset for a $45 million payment, a key step in its ongoing strategy to expand its oncology pipeline with innovative targeted protein degradation (TPD) therapies. This decision follows a successful collaboration period where Gilead evaluated the compound's potential, which is being developed for the treatment of certain cancers, including cyclin E-amplified tumors, where CDK2 is a critical driver of tumor growth. The partnership between Gilead and Kymera, initially formed in 2023, is centered on advancing the field of TPD, a cutting-edge therapeutic modality that aims to eliminate disease-causing proteins rather than just inhibiting them. KT-333 represents a promising approach in this space, specifically designed to degrade CDK2, a protein involved in cell cycle regulation that is often dysregulated in various cancers. By exercising this option, Gilead is now positioned to lead the further clinical development and potential commercialization of the drug, leveraging its extensive resources and global reach in the pharmaceutical industry. This $45 million deal underscores the growing value and competitive interest in targeted protein degraders within the biopharma sector. For Kymera, the payment provides non-dilutive capital to fund its research and development efforts on other programs in its pipeline. The transaction highlights a trend where larger pharmaceutical companies are actively partnering with or acquiring innovative biotechs to access next-generation technologies, particularly in oncology. The success of this collaboration could pave the way for future milestones and royalties for Kymera, depending on the drug's progress through clinical trials and eventual regulatory approval.